Descripción de la empresa
NextCure, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic medicines specifically designed to treat cancer. The company functions within the broader healthcare sector and the specialized biotechnology industry, a landscape defined by high research and development costs and long product development cycles. The organization employs a workforce of 40 individuals and holds a total market capitalization of $35.64 million. These financial figures indicate that the company is a micro-cap entity with limited market penetration and revenue generation capabilities relative to its peers, reflecting its status as a pre-revenue or early-stage development company where value is derived primarily from intellectual property and pipeline potential rather than established sales volumes.
Salud financiera
The company reports revenue of N/A for the trailing twelve months, while net income stands at a loss of $-55,844,000 and EBITDA is recorded at $-55,431,000. The substantial gap between revenue and net income, combined with the absence of reported revenue, reveals a cost structure dominated by significant research and development expenditures and operational overhead that have not yet been offset by commercial sales. Free cash flow is reported at $-28,799,000, indicating that the company is burning cash at a rapid pace, which limits its immediate financial flexibility and necessitates access to capital markets or existing reserves to fund ongoing operations. All three margin metrics—gross margin, operating margin, and profit margin—are listed at 0.0%, a figure that signifies the company has not yet achieved profitability or generated meaningful sales to calculate standard percentage margins. On the balance sheet, the company holds $41.82 million in cash against $5.15 million in debt, resulting in a debt-to-equity ratio of 14.75. This high debt-to-equity figure suggests a leveraged capital structure, yet the abundant cash reserves provide a buffer that mitigates immediate solvency concerns despite the lack of earnings. The current ratio is 4.14, which indicates a robust position regarding short-term liquidity, as the company possesses more than four times the current assets required to cover its short-term liabilities. Return on equity is -111.2% and return on assets is -55.0%, metrics that reveal that management has not yet generated positive returns on the capital invested in the business, a common characteristic of clinical-stage biotechnology firms still in the investment phase.
Evaluación de valoración
The trailing twelve-month P/E ratio is N/A due to the absence of earnings, while the forward P/E is listed as -1.59. The discrepancy between these figures, particularly the negative forward P/E, implies that analysts or data providers project continued negative earnings or are using alternative methods to value the stock in the absence of positive earnings growth. The price-to-book ratio is 1.00, suggesting that the market values the company's equity at par with its book value, which often occurs when a company lacks significant tangible assets or when intangible assets like intellectual property are not fully captured on the balance sheet. Price-to-sales ratio data is N/A, and the EV/EBITDA stands at 0.02, metrics that suggest the company is valued extremely low relative to its enterprise value and earnings multiple, a reflection of the high risk associated with clinical-stage assets. The stock has traded between a 52-week high of $15.74 and a 52-week low of $2.69, meaning the current price sits significantly below the recent peak, reflecting the volatility typical of small-cap biotechnology stocks. The beta is 1.55, which indicates that the stock price is expected to be 55% more volatile than the broader market, exposing investors to higher fluctuations in share price during periods of market stress or stability.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company has not yet established a consistent revenue base to calculate meaningful growth rates. Consequently, there is no historical data to determine whether earnings are growing faster or slower than revenue, as both metrics are currently undefined for a pre-revenue entity. NextCure, Inc. does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the company reinvests all available cash flow and reserves into research, development, and operational expansion rather than distributing income to shareholders. The overall growth and income profile is characterized by a total lack of current commercial revenue and earnings, with the company relying entirely on its cash reserves to fuel the development of product candidates like LNCB74 and NC410 until they reach marketable stages.